Setting
Two primary care practices in Tauranga, New Zealand.
Participants
There were 15 adult participants with a doctor's diagnosis of eczema involving the limbs, with bilateral lesions to allow comparison between treatments. Exclusion criteria were any corticosteroid use, requirement for antibiotic treatment or allergy to honey.
Main outcome measures
Primary outcome measure was the lesion component of the validated SCORing Atopic Dermatitis measure, 2, 3 assessed by a second investigator blinded to treatment allocation. Secondary outcome measures were Three Item Severity (TIS) score 3 measured by the blinded investigator, unblinded measures were participant rated itch severity and acceptability of honey therapy, both measured by visual analogue score. The study was approved by the Multi-Region Ethics Committee of New Zealand (NZ), MEC-11-12-098, and written informed consent was obtained from all participants. One sample t-tests were used to estimate the difference between sides administered honey or control. An exact binomial method was used to calculate the confidence interval for the proportion of those with an adverse event. The sample size of 15 was chosen on the basis of variance estimation rather than to detect clinically important differences.
Results
The majority of subjects were women (8/15) and all subjects were included in the analysis, mean (SD) age 37.1 (12.1). Acceptability of honey therapy was moderate with mean duration of application over 8 hours, results shown in Table 1 . Mean (95% confidence interval) eczema severity was similar in honey and control groups at baseline, honey minus control À0.5 (À2.2 to 1.3). After 2 weeks, treatment change in lesion intensity was not different between groups, À0.1 (À1.5 to 1.4). TIS and subjective itch scores were also similar for honey and control, À0.1 (À0.9 to 0.6) and À7.3 (À27.7 to 13.2), respectively. One participant reported increased itch with honey application.
Conclusions
In this pilot single-blind randomized controlled trial of topical medical-grade Kanuka honey for the treatment of eczema, Kanuka honey treatment was found to be feasible with moderate acceptability. There was no evidence of efficacy above that of the aqueous cream control. Aqueous cream is not recommended as a treatment in eczema and represents a negative control. 4 Important limitations of this study are the small sample size, which means that we cannot rule out a small but clinically important response to topical honey, and incomplete blinding due to the physical characteristics of honey.
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